NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to ...
Cibus, Inc. announced significant advancements in its gene editing technology, particularly the establishment of production standards for its proprietary RTDS gene editing system, which enables the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results